Navigation Links
Group of anti-diabetic drugs can significantly lower cancer risk in women with type 2 diabetes
Date:12/5/2013

Thursday, Dec. 5, 2013, Cleveland: A Cleveland Clinic-led study shows that a specific type of diabetes drug can decrease the risk of cancer in female patients with type 2 diabetes by up to 32 percent.

People with type 2 diabetes have a higher rate of cancer development and recurrence compared to the general population. This study published online today by the journal Diabetes, Obesity and Metabolism shows that widely prescribed anti-diabetes drugs can be linked to either an increased or decreased risk of cancer, depending on the type of medication prescribed.

A team of researchers led by Sangeeta Kashyap, M.D., an endocrinologist and associate professor of medicine at Cleveland Clinic's Endocrinology & Metabolism Institute, compared two groups of drugs commonly used to treat type 2 diabetes insulin sensitizers and insulin secretagogues. Insulin sensitizers lower blood sugar and insulin levels in the body by increasing the muscle, fat and liver's response to insulin. Insulin secretagogues lower blood sugar by stimulating pancreatic beta cells to make more insulin.

"What this study shows us is that using insulin secretagogues to increase insulin production correlates with an increased cancer risk in women with type 2 diabetes," said Kashyap. "By contrast, insulin sensitizers cut insulin levels and can decrease cancer growth. So, clearly, when prescribing anti-diabetic medications, it's important to consider the impact a drug has on fueling cancer growth."

In a retrospective analysis, researchers cross-indexed the electronic health record-based Cleveland Clinic Diabetes Registry (25,613 patients) with the histology-based tumor registry (48,051 cancer occurrences) over an 8-year period (19982006). More than 890 incident cancer cases were identified. The two most common cancers were prostate and breast, accounting for more than 25 percent of total cancer cases.

Study results show that the use of insulin sensitizers in female patients with type 2 diabetes was associated with a 21 percent decreased cancer risk compared with insulin secretagogues. Furthermore, the use of a specific insulin sensitizer, thiazolidinedione, was associated with a 32 percent decreased cancer risk in female patients compared with sulphonylurea, an insulin secretagogue. Results showed no significant difference in men.

The findings in this study contribute to existing research in the field on diabetic patients and their increased cancer risk. Further research is needed to examine the impact of oral diabetes therapy on cancer risk and development.


'/>"/>

Contact: Caroline Auger
augerc@ccf.org
216-636-5874
Cleveland Clinic
Source:Eurekalert

Related medicine news :

1. Physician Groups Call for Fewer Medical Tests
2. From herd immunity and complacency to group panic: How vaccine scares unfold
3. Study finds significant skull differences between closely linked groups
4. Diabetes Groups Issue New Guidelines on Blood Sugar
5. Small neural focus groups predict anti-smoking ad success
6. Group B streptococcal meningitis has long-term effects on childrens developmental outcomes
7. The Attilio Group’s TAG™-Simply Faster Taps SmartSales To Accelerate Its Expansion Into National Reach
8. Infants cant distinguish between large and small groups
9. Rush joins elite group of institutions with accredited research programs
10. The Casey Group's Sales Navigator Wins 2012 Best Mobility App in the New Jersey Technology Council's Mobile Application Competition
11. Artisan Business Group hosts EB-5 Conference in California
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... , ... Quality metrics are proliferating in cancer care, and are derived from ... of the beholder, according to experts who offered insights and commentary in the current ... For the full issue, click here . , For the American Society of ...
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room ... Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, ... Elite. The attorneys chosen by their peers for this recognition are considered among the ... Traurig Shareholders received special honors as members of this year’s Legal Elite Hall of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
(Date:6/23/2016)... June 23, 2016 Any dentist who has made ... the current process. Many of them do not even offer ... difficulties and high laboratory costs involved. And those who ARE ... at such a high cost that the majority of today,s ... Dr. Parsa Zadeh , founder of Dental Evolutions Inc. ...
(Date:6/23/2016)... ANGELES , June 23, 2016 ... CAPR ), a biotechnology company focused ... therapeutics, today announced that patient enrollment in its ... in Duchenne) has exceeded 50% of its 24-patient ... enrollment in the third quarter of 2016, and ...
Breaking Medicine Technology: